NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh

NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh

KKRX:950220
1,485.00
KRW
-9.00
(-0.60%)
-527.25EPS
8.82BMarket Cap

Total Valuation

KRW

As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh carries a market capitalization of 8.82B, placing it among publicly traded companies globally. Its enterprise value stands at -27.17B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap8.82B
Enterprise Value-27.17B

Share Statistics

As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh has 6.71M shares outstanding.

Shares Outstanding6.71M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 34.89, and the price-to-book ratio stands at 0.16.

PS Ratio34.89
PB Ratio0.16
P/TBV Ratio0.24
P/FCF Ratio-2.19
P/OCF Ratio-2.59

Financial Position

As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh maintains a current ratio of 2.83, meaning it holds 2.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 20.01, indicating elevated leverage, while an interest coverage ratio of -30.88 demonstrates limited ability to service its debt obligations.

Current Ratio2.83
Quick Ratio2.60
Debt / Equity20.01
Debt / EBITDA-0.61
Interest Coverage-30.88

Financial Efficiency

KRW

Over the twelve months ended June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh posted a negative return on equity (ROE) of -61.20, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -39.27, reflecting losses generated across the asset base. The company generates approximately 40.78M in revenue per employee across its workforce of 43.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-61.20
Return on Assets (ROA)-39.27
Revenue Per Employee40.78M
Employee Count43.00

Taxes

KRW

Over the twelve months ended June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh recorded 12.56M in income tax expense. The company reported a pretax loss of -24.50B and -24.52B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

Income Tax12.56M

Stock Price Statistics

KRW

As of the close on November 17, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh's stock has declined approximately 50.08% over the past 52 weeks. The 50-day moving average sits at 1,839.54, while the 200-day moving average is 2,280.22.

52-Week Price Change-50.08%
50-Day Moving Average1,839.54
200-Day Moving Average2,280.22

Income Statement

KRW

Over the twelve months ended June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh generated 1.75B in revenue and converted that into -24.52B in net income, yielding earnings per share of -527.25. EBITDA reached -18.58B, while operating income came in at -21.05B.

Revenue1.75B
Gross Profit1.63B
Operating Income-21.05B
Pretax Income-24.50B
Net Income-24.52B
EBITDA-18.58B
EBIT-21.05B
Earnings Per Share (EPS)-527.25

Balance Sheet

KRW

As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh holds 47.28B in cash and equivalents against 11.28B in total debt, resulting in a net debt position of -26.36B. Total book value stands at 56.38B, with working capital of 33.25B providing operational flexibility.

Cash & Cash Equivalents47.28B
Total Debt11.28B
Net Debt-26.36B
Equity (Book Value)56.38B
Book Value Per Share8,407.92
Working Capital33.25B

Cash Flow

KRW

NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh produced -23.64B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -4.31B in capital expenditures, free cash flow totaled -27.95B - equivalent to -601.08 per share.

Operating Cash Flow-23.64B
Capital Expenditures-4.31B
Free Cash Flow-27.95B
FCF Per Share-601.08

Margins

These figures cover the twelve months ended June 30, 2026. The operating margin of -1,200.62 and net profit margin of -1,397.95 provide insight into operational efficiency.

Operating Margin-1,200.62
Pretax Margin-1,397.23
Profit Margin-1,397.95
EBITDA Margin-1,059.47

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -45.67: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -548.15, meaning NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-548.15
FCF Yield-45.67

Stock Splits

NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh's most recent stock split took place on June 10, 2026 with a 5:1 split ratio.

Last Split Date6/10/2026
Split Ratio5:1

Scores

As of June 30, 2026, NeoImmuneTech Inc shs Korean Deposit Receipt Repr 1/5 Sh has an Altman Z-Score of -9.83, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-9.83